chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pain in arms; red velt; little mental; fogginess; little lump; This spontaneous case was reported by a nurse and describes the occurrence of PAIN IN EXTREMITY (Pain in arms), ERYTHEMA (red velt), MENTAL DISORDER (little mental), FEELING ABNORMAL (fogginess) and MASS EXCISION (little lump) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029K20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No adverse event reported).    On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Feb-2021, the patient experienced PAIN IN EXTREMITY (Pain in arms), ERYTHEMA (red velt), MENTAL DISORDER (little mental), FEELING ABNORMAL (fogginess) and MASS EXCISION (little lump). On 01-Feb-2021, MENTAL DISORDER (little mental), FEELING ABNORMAL (fogginess) and MASS EXCISION (little lump) outcome was unknown. At the time of the report, PAIN IN EXTREMITY (Pain in arms) and ERYTHEMA (red velt) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications reported were blood pressure medicine, cholesterol medicine. Treatment details included Warm cloth.
heart palpitations; tingling in his arm; This is a spontaneous report from a contactable consumer (patient). A 68-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route of administration on 06Feb2021 (Batch/Lot number was not reported) as 1st dose, single for COVID-19 immunisation. Medical history included anxiety. The patient's concomitant medications were not reported.  The Thursday after receiving his first dose of the vaccine, on 11Feb2021, the patient started experiencing tingling in his arm and heart palpitations. He was seen in the Emergency Room and he had a full cardiac work up completed. He was cleared by cardiology and was given the diagnosis of heart palpitations. He has spoken with his HCP and Cardiologist about the safety of receiving the second dose of the Pfizer COVID-19 vaccine and if these palpitations could have been a result from receiving the first dose. Both of his doctors agree that he should proceed with receiving the second dose of the vaccine. The caller states that he was not sure if this event happened because of receiving the vaccine or because of anxiety. The outcome of events was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Pt. fainted while vaccine was in arm.  I called a CODE 100 and put a cold water bottle on the patient's neck.  Pt. came to within seconds.  Pt. came to profusely sweating, pale, and feeling dizzy.  We took his BP and kept monitoring it for 45 minutes after we had him lay down.  His BP continued to rise and was normal.  Pt. was nervous before vaccine administration (shaking).  After event, Pt. stated this has happened in the past with donating blood.  Pt.'s girlfriend picked him up, so he did not drive home.
administrated with Bexsero after a below freezing temperature excursion; This case was reported by a physician via call center representative and described the occurrence of incorrect storage of drug in a 17-year-old male patient who received Men B NVS (Bexsero) (batch number unknown, expiry date 21st March 2022) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 19th July 2021, the patient received Bexsero and Bexsero Pre-Filled Syringe Device. On an unknown date, unknown after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional case details were provided as follows: Physician reported that the patient was administrated with Bexsero after a below freezing temperature excursion which led to incorrect storage of drug.  No adverse event was reported. The reporter consented to follow up. This case was 1 of 28 case reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021164791:same reporter US-GLAXOSMITHKLINE-US2021164781:same reporter US-GLAXOSMITHKLINE-US2021164787:same reporter US-GLAXOSMITHKLINE-US2021164783:same reporter US-GLAXOSMITHKLINE-US2021164777:same reporter US-GLAXOSMITHKLINE-US2021164779:same reporter US-GLAXOSMITHKLINE-US2021164775:same reporter US-GLAXOSMITHKLINE-US2021164771:same reporter US-GLAXOSMITHKLINE-US2021164801:same reporter US-GLAXOSMITHKLINE-US2021164769:same reporter US-GLAXOSMITHKLINE-US2021164800:same reporter US-GLAXOSMITHKLINE-US2021164784:same reporter US-GLAXOSMITHKLINE-US2021164788:same reporter US-GLAXOSMITHKLINE-US2021164784:same reporter US-GLAXOSMITHKLINE-US2021164786:same reporter US-GLAXOSMITHKLINE-US2021164788:same reporter US-GLAXOSMITHKLINE-US2021164789:same reporter US-GLAXOSMITHKLINE-US2021164792:same reporter US-GLAXOSMITHKLINE-US2021164793:same reporter US-GLAXOSMITHKLINE-US2021164794:same reporter US-GLAXOSMITHKLINE-US2021164795:same reporter US-GLAXOSMITHKLINE-US2021164797:same reporter US-GLAXOSMITHKLINE-US2021164798:same reporter US-GLAXOSMITHKLINE-US2021164799:same reporter US-GLAXOSMITHKLINE-US2021164804:same reporter US-GLAXOSMITHKLINE-US2021164805:same reporter US-GLAXOSMITHKLINE-US2021164806:same reporter US-GLAXOSMITHKLINE-US2021164808:same reporter
Unexplainable rash, uncontrollable hives/ welts all over body. Blood clot in left lung.
pt recv vax & broke out in hives-one the size of an orange, the other the size of a quarter will not give further hep B vax; tx w/atarax;
This is a spontaneous report from a contactable physician from the Merck National Service Center under the service request number 1-5623366185. A patient of unspecified age, ethnicity, and gender received PREVNAR via an unspecified route of administration on an unspecified date. The patient medical history was not reported. The patient's concomitant medications were not reported. On an unspecified date, the patient developed pneumonia. The outcome of the event, pneumonia, was unknown at the time of the report. Follow-up (14Dec2012): Follow-up attempts completed. No further information expected. Follow-up (21Dec2012): New information received from a contactable physician includes: the physician could not confirm the reported event as the physician could not confirm which patient the event was referring to. Follow-up attempts completed. No further information expected.
No adverse effect reported.  Patient potentially received Moderna COVAX 0.5 mL versus the correct dosage of Moderna COVAX 0.25 mL The Moderna COVAX 6mos to 4yrs old is clearly labeled as ?0.25 mL single dose vial? however I did the investigation and found that the single dose vials we have on hand indeed have 0.5 mL inside of it .
Kinrix given to patient age 2 yr; Kinrix (3rd dose Dtap/IPV) given to child 2yr; This case was reported by a other health professional via (Shingrix GSK Chatbot) interactive digital media and described the occurrence of inappropriate age at vaccine administration in a 2-year-old patient who received DTPa-IPV (Kinrix) for prophylaxis.   Co-suspect products included dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Dtap (received in 10th July 2019) and IPV (received in 16th September 2019).   On an unknown date, the patient received Kinrix and Kinrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Kinrix and Kinrix Pre-Filled Syringe Device, the patient experienced inappropriate age at vaccine administration and inappropriate schedule of vaccine administered. On an unknown date, the outcome of the inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as the patient previously received Dtap and IVP vaccine. The 2 year 5 months patient was mistakenly administered Kinrix, which led to inappropriate age at vaccine administration, and inappropriate schedule of vaccine administered. The reporter enquired would this hurt the patient and if there was need to repeat the doses with non Kinrix or just give Kinrix again at age 4 years.
Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Medium, Systemic: Tingling (specify: facial area, extemities)-Medium, Additional Details: tingling in both arms and pressure onhead right after vaccine was given . came to pharmacy and i told her to stay another 30 minutes and she still had when left. I told her to follow up with dr. tingling was a side effect of the vaccine . when she got home and later starting to have throat tightness and tongue swelling. she drank water and it help. She took an IBU at 5pm. She came to the pharmacy on 8/5/21. She continues to have tingling&tightnI told her to take some benadryl and needs to see dr
Narrative:  PATIENT WITH COVID-19 INFECTION FOLLOWING BEING FULLY VACCINATED. PATIENT REQUIRED AN INPATIENT STAY WITH HIGH-FLOW OXYGEN, REMDESIVIR, DEXAMETHASONE AND TOCILZUMAB TREATMENT. FURTHER LAB TESTING SHOWED UK STRAIN OF COVID-19.
Acute on chronic abdominal pain and cramping 2/2 COVID-19 & acute hypoxemic respiratory failure 2/2 COVID-19 PNA requiring hospitalization
Left deltoid swollen from shoulder to elbow all the way around arm.  Deltoid area hard, red, warm to the touch.  Child ran low grad fever.  Symptoms began 5/29/08.  Given Tylenol and Motrin.  Dr. called, suggested Benadryl
After pain in the arm where shot was administrated, over heat and itchy in the area for 3 days, disappeared. After 2 days same reaction came back for another 3 days, disappeared A third time with same symptoms: heat, pain and itchy. After a consultation with  a doctor, he determined it was a localized reaction, use hydrocortisone 1% creame. After 12 hours al symptoms were gone.
Sudden onset of high blood glucose (more than 500 mg/dL) about 2 weeks after vaccination with no family history of DM, no history of chronic illnesses and no other apparent risk factors!
THE PT DOES NOT HAVE ANY REACTION, HER PARENTS ARE AGREE TO BRING HER BACK AND GET A NEW DOSE OF COVID 19 VACCINE, NO ADVERSE EVENTS, SYMPTOMS OR SIGNS. I HAVE THE COVID SHOT AND IT WAS DRAW FOR MORE THAN 12 HRS. 12/29/2021 AROUND 10:30 AM
Severe pain at injection sight 5 minutes after injection. Dizziness 10 minutes after injection and lasting 15-20 minutes. Nausea the next morning  starting at 9:30 am and continuing for at least 4 hours.
Pt. observed coming in and out of consciousness.  Pt. remains unstable and transported to Medical Center.  90/40, HR 32,  RR 22.
Fever (99.5) chills, lower abdominal pain, severe muscle aches, headache.
Received Moderna vaccines on 8/9/21, 9/7/21 COVID-19 positive by PCR on 1/8 admitted to hospital on 1/11 d/t abd pain, underlying h/o metastatic urethral cancer found to be COVID + on admit, treated w/ Remdesivir
ACUTE RESPIRATORY FAILURE 2/21/2023 CKD STAGE 3A (GFR 45-59)
swelling; pruritus; This spontaneous case was reported by a consumer and describes the occurrence of   in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 14 dosage form.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided.  No treatment information provided.   Reporter did not allow further contact
Stiff arm today. However, patient received second Pfizer COVID vaccine 14 days after first dose instead of 21 days after first dose.
I did not have a reaction to the vaccine. Exposed to COVID-19 with children I was watching. I tested positive for COVID-19 on 12/05/2022. I also had a PCR test on 12/06/2022 to confirm COVID-19 positive. I had a headache, runny nose, cough, very tired and nasal congestion. I contacted a provider and was given the prescription PAXLOVID.
Information has been received from a registered nurse referring to a 30 year old patient of unknown gender. The patient's concurrent condition, historical condition and concomitant therapy were not reported. On unspecified dates, the patient was "vaccinated in childhood" with an unknown number of doses of PEDVAXHIB (strength, dosage, frequency, lot#, route and expiration date were not provided). The reporter reported that the patient was currently "immunosuppressed". It was unknown by reporter if patient was "immunosuppressed" prior to being "vaccinated in childhood" with of PEDVAXHIB. The outcome of the event was unknown.  The causality between the event and the vaccine was not reported. Upon internal review, "immunosuppressed" was considered to be medically significant.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 60-year-old male patient received BNT162b2 (BNT162B2), on 05May2021 as dose 2, single (Lot number: EW0179) at the age of 59 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Diarrhoea" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Advil, reaction(s): "Known allergies: Yes, advil family and related RX".  The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown Results, notes: Indication: Treatment of COVID-19. Therapeutic measures were taken as a result of drug ineffective, suspected covid-19. Clinical course: Patient received other medication in 2weeks product: colestipol, start date: 03Apr2022.
My left arm was sore at the injection site for approximately two days after the shot on March 1st.  That has resolved by the third day.  However,  when I woke up on March 8th, my upper arm around the injection site was very itchy, warm, red and the skin was hard & slightly raised.  The itchiness is better today but the area is still warm, red, hard & raised.  Have just used ice when at home and not at work.  Hope that it will improve with time.
This spontaneous report was received from a nurse refers to a patient of unknown age and gender. Information on pertinent medical history and drug reactions/allergies were not reported. On 05-MAR-2018 (reported as today), a patient was vaccinated with an improperly stored dose (reported as one shot) of VARIVAX injection (strength, dose and route of administration were not reported) (lot # N024568, expiry date: 07-SEP-2019) for prophylaxis. The vaccine was reconstituted with properly stored sterile diluent (manufacturer unknown) (lot # N013282, expiry date: 28-AUG-2019). The administered VARIVAX had undergone a temperature excursion of 15 degrees Fahrenheit (F) to 46 F (28.1 F) for 4 hour and 44 minutes. There was no previous temperature excursion. The digital data logger was involved in recording the temperature excursion. On 05-MAR-2018, the patient was also vaccinated with properly stored dose (reported as one shot) of M-M-R II (lot # N013868, expiry date: 04-MAY-2019, therapy type: RHA). No adverse effects were reported. There was no product quality complaint (PQC) reported. No further adverse event information was reported.
At an unspecified time after vaccination with BOOSTRIX, the subject experienced a red spot at injection site. The pharmacist described the spot as "red circular spot around injection site". The pharmacist stated that the vaccination was administered at a different location other than the pharmacy. At the time of reporting the outcome of the event was unspecified. The pharmacist reported another case of adverse events with BOOSTRIX. The pharmacist was contacted by the subject to ask about her husband's reaction. See case A0997907A for details.
Full body aches began 6 hours after injection and lasted for about 30 hours. Once the aches started my left arm gained a bluish tint from injection site to fingertips. This is still an ongoing issue. Also once the aches began I got several little itchy bumps on the left side of my body which developed into big patches of hives/heat blisters within a day that are extremely itchy. The worst outbreak happened on my left lower shin. Two and  half weeks later it is still ongoing. There is swelling and discoloration and the blisters seep out and then build up a hard thick scab. It seems to still spread and the itching is unbearable.
Pt states she had red spot about 1.5"x3/4" in size about 2" from site of vaccine. Denies pain or itching. Started today (one day after administration). Advised pt to use TYLENOL and BENADRYL if necessary as well as cool compresses and to advise if it gets worse.
pain traveled below underarm into right breast, still remaining in right back; pain traveled below underarm into right breast, still remaining in right back; totally incapacitated; felt like there was a foot embedded in the right back/pain was excruciating; difficult to find a position to sleep; This is a spontaneous report from a contactable consumer (patient). A 67-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration in the left upper arm, on 27Feb2021 at 13:00 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis, diabetes, high blood pressure, thyroid, pregnancy from 1985 to 1986 (last menstrual period (LMP) reported as 21Aug1985), sulfa allergy, and angiotensin-converting enzyme (ACE) inhibitor allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included tofacitinib citrate (XELJANZ), metformin (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN), and imipramine (MANUFACTURER UNKNOWN). The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced felt like there was a foot embedded in the right back/pain was excruciating and difficult to find a position to sleep on 28Feb2021 at 22:00 and pain traveled below underarm into right breast, still remaining in right back and totally incapacitated on 01Mar2021. The clinical course was reported as follows: The patient woke up the next morning after vaccination feeling like there was a foot embedded in her right back and the pain was excruciating to the point that she was moaning out in pain. The patient reached out to her primary care physician, who told her to give it 36 hours. That same night, the patient found it difficult to find a position to sleep and ended up on her left side. When she woke up the following morning, the pain had traveled below the underarm into her right breast, along with still remaining in the right back. She was still in excruciating pain and totally incapacitated. She stated she could not imagine experiencing this same reaction from a second dose. The patient did not receive any treatment as a result of the events. The clinical outcome of felt like there was a foot embedded in the right back/pain was excruciating, difficult to find a position to sleep, pain traveled below underarm into right breast, still remaining in right back, and totally incapacitated was recovered in 2021. It was also reported that since the vaccination, the patient had not been tested for COVID-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
1 1/2 minutes starving, would not respond to any stimulation. Fever of 103.2F.
Within 24 hours post vax, the pt developed an injection site reaction characterized by an area of redness, pain, and swelling measuring approximately 3" in diameter.
Local erythema and swelling L posterior upper arm immediately after MMRV injection. Observed for 15 min after vaccine, no progression of sx's; redness decreased
Patient reported receiving second Pfizer vaccine on 5/5/21 and becoming dizzy that evening after administering his Palynziq injections. He also reported this happened the evening after he received the first Pfizer vaccine too, but did not disclose the vaccination date. He confirmed that he has not, at any other time, experienced dizziness after injecting his Palynziq.
I am experiencing a bad case of diarrhea since the end of April and have been into the Doctor several times and all the tests run came back negative. I'm on anti-diarrhea medication (Lomotil) which is helping somewhat but I don't like taking medicine because I have to rely on the medication to perform my daily routine plus having to wear pads all the time is an inconvenience for me. I had to go to the ER because I had a episode of near fainting.
Per Vaccine recipient approximately 4-4 1/2 hours after receiving vaccine she noticed  facial swelling in and around nose, to neck area, to R elbow and a petechial rash near R elbow. She immediately took Benadryl and Pepcid and then went to ER for further evaluation, where she was given a dose of Zyrtec and 5 day course of Prednisone. She left ER with no further complication.
Acute onset episodes of nausea, dizziness and abdominal pain daily since the day after vaccination administration.